PEPVAC -- a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands

What you can do:
Develop fully covering multi-epitope vaccines against pathogenic organisms based on genome wide predictions of promiscuous MHCI-restricted epitopes.
  • This Web server, PEPVAC (Promiscuous EPitope-based VACcine), is optimized for the formulation of multi-epitope vaccines with broad population coverage.
  • This optimization is accomplished through the prediction of peptides that bind to several HLA molecules with similar peptide-binding specificity (supertypes).
  • Specifically, it offers the possibility of identifying promiscuous peptide binders to five distinct HLA class I supertypes (A2, A3, B7, A24 and B15). It is estimated the phenotypic population frequency of these supertypes to be 95%, regardless of ethnicity.
  • Targeting these supertypes for promiscuous peptide-binding predictions results in a limited number of potential epitopes without compromising the population coverage required for practical vaccine design considerations.
  • PEPVAC can also identify conserved MHC ligands, as well as those with a C-terminus resulting from proteasomal cleavage. The combination of these features with the prediction of promiscuous HLA class I ligands further limits the number of potential epitopes.
  • major histocompatibility complex
  • MHC
  • T-cell epitopes
  • multi-epitope vaccines
  • multi-epitope vaccines design tool
  • human leukocyte antigens
  • HLAs
  • HLA-A Antigens
  • HLA-B Antigens
  • Proteasome Endopeptidase Complex
  • promiscuous HLA class I ligands prediction tool
  • conserved MHC ligands identification tool
This record last updated: 04-25-2006
Report a missing or misdirected URL.

The Health Sciences Library System supports the Health Sciences at the University of Pittsburgh.

© 1996 - 2023 Health Sciences Library System, University of Pittsburgh. All rights reserved.